Answers are grounded in this paper and cite their sources.
Scope SlimTrym® is a formulated product composed of citrus polymethoxyflavones (PMFs), green tea extract, and lychee extract. We investigated the effect of dietary SlimTrym® on diet‐induced obesity and associated non‐alcoholic fatty liver disease (NAFLD) in mice. Methods and results Male C57BL/6 mice were fed a normal diet (ND), high fat diet (HFD) or HFD containing 0.1% or 0.5% SlimTrym® for 16 weeks. Dietary SlimTrym® significantly reduced weight gain and relative perigonadal, retroperitoneal, mesenteric fat weight as well as the size of adipocyte in HFD‐fed mice. SlimTrym® supplementation also effectively diminished hepatic steatosis and the serum levels of glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), triacylglycerol (TG), and total cholesterol (TCHO). Down‐regulation of peroxisome proliferator‐activated receptor (PPAR)γ, sterol regulatory element‐binding protein (SREBP)‐1, and the activation of AMP‐activated protein kinase (AMPK) signaling by SlimTrym® in both adipose tissue and liver may be responsible for the observed anti‐obesity effects. Conclusion SlimTrym® supplementation potentially diminished diet‐induced obesity and hepatic steatosis via regulating AMPK signaling and molecules involved in lipid metabolism.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: